ARTICLE | Clinical News
GPI-0100: Phase I data
February 28, 2005 8:00 AM UTC
In a dose-escalation, U.S. Phase I trial in 42 evaluable patients with relapsed prostate cancer, GPI-0100 used in combination with a bivalent vaccine was well tolerated and led to a dose-dependent enh...